Phase II Feasibility and Biomarker Study of Neoadjuvant...

  • Main
  • 2019 / 12
  • Phase II Feasibility and Biomarker Study of Neoadjuvant...

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

Stroes, Charlotte I., Schokker, Sandor, Creemers, Aafke, Molenaar, Remco J., Hulshof, Maarten C.C.M., van der Woude, Stephanie O., Bennink, Roel J., Mathôt, Ron A.A., Krishnadath, Kausilia K., Punt, C
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.19.01814
Date:
December, 2019
File:
PDF, 934 KB
2019
Conversion to is in progress
Conversion to is failed